Ethotoin

Summary

Ethotoin (CHEMBL1095) is an approved small-molecule anticonvulsant (ATC N03AB01); indicated across 2 conditions including epilepsy and visual epilepsy.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N03AB01
• Indications: 2 conditions
• Chemistry: 204.22 Da · C11H12N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1095
Name	Ethotoin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3292
ChEBI	CHEBI:4888
ATC	N03AB01
Molecular formula	C11H12N2O2
Molecular weight	204.22
InChIKey	SZQIFWWUIBRPBZ-UHFFFAOYSA-N

SMILES: CCN1C(=O)C(NC1=O)C2=CC=CC=C2

IUPAC name: 3-ethyl-5-phenylimidazolidine-2,4-dione

ChEBI definition: An imidazolidine-2,4-dione that is hydantoin substituted by ethyl and phenyl at positions 3 and 5, respectively. An antiepileptic, it is less toxic than phenytoin but also less effective.

Pharmacological roles (ChEBI): anticonvulsant.

Also known as: Accenon, Ethotoin, Ethotoine, Etotoina, NSC-760074, Peganone, ETHOTOIN, SID56463534, ethotoin, ETHOTOINE, SID144203934

Patent coverage: 1,308 distinct patent families (5,435 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Adenosine receptor A3, Prostaglandin G/H synthase 1.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
epilepsy	4	MONDO:0005027	EFO:0000474
visual epilepsy	4	MONDO:0001386	HP:0001250

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).